Humira biosimilars arrive in the US, as Amgen launches first copycat to AbbVie’s blockbuster drug

The monopoly protecting the world’s best-selling medicine is at an end. On Tuesday, Amgen is launching a copycat version of AbbVie’s autoimmune disease drug Humira in the U.S., giving physicians and people with conditions like arthritis, psoriasis and Crohn’s disease a lower-cost option to a treatment now priced at nearly $90,000 a year.